About Kairos Pharma, Ltd. (KAPA) data
Data as of September 30, 2026.
Kairos Pharma, Ltd. (KAPA) has 113.18K shares sold short as of the latest FINRA settlement report on September 30, 2026. Short interest has decreased by 1.06% compared with the prior settlement. At the current average daily volume, covering all open short positions would take about 1.04 days (days to cover).
Frequently asked questions
What is the current short interest in KAPA?
As of the latest FINRA settlement dated September 30, 2026, KAPA had approximately 113,181 shares sold short. Short interest data is reported by FINRA twice per month.
How much does it cost to short KAPA?
The latest borrow fee (cost to borrow) for KAPA is 11.93% per year, based on IBKR data. Fees can change throughout the trading day as shares are borrowed and returned.
What is the days to cover ratio for KAPA?
Days to cover for KAPA is approximately 1.04 days. This estimates how many trading days it would take short sellers to buy back all outstanding short shares at the current average daily volume.
How many KAPA shares failed to deliver?
On September 30, 2026, the latest settlement date in the SEC's fails-to-deliver data, 263 shares of KAPA had failed to deliver, worth about $436.58 at the prior day's close (under 0.01% of shares outstanding). That is the balance still outstanding that day, not new fails. Fails come from long sales and delivery delays as well as short sales.
Is KAPA a short squeeze candidate?
A squeeze needs shorts that are hard to close. KAPA trades about 108,708 shares a day and would take roughly 1.04 days to unwind current short positions, at a current borrow fee of 11.93%. Higher days-to-cover and a rising borrow fee together are the setup to watch; neither alone is enough.